EGFR and non-small cell lung carcinoma: The discovery of an epidermal growth factor receptor (EGFR)-sensitive mutation and the development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) pioneered targeted therapy for NSCLC.